Esticast Logo
Get In Touch!

Generic Drugs Market By Brand (Pure generic drugs, Branded generic drugs), By Therapeutic Application (Central nervous system (CNS), Cardiovascular, Dermatology, Oncology, Respiratory), Industry Trends, Estimation & Forecast, 2018-2025

Generic Drugs Market is expected to grow with a CAGR of 8% during the forecast period of 2018 to 2025.

Market Overview:

Generic drugs are pharmacologically equivalent drugs to the patented ones, containing same active pharmaceutical ingredient, but available at reduced costs in comparison to the patented drugs, owing to the absence of R&D as well as novel drug development costs. Increasing number of patent expiration of branded drugs is one of the major reasons which is stimulating the market growth. This is because patent expirations allow the generic drug manufacturers to enter the market with bioequivalent drugs. For example, generic imatinib by Sun Pharma is priced 30% below the branded drug’s price. Apart from that, various government initiatives to bring more generic drugs in the market is also boosting the market growth. The Hatch-Waxman Act has made the entry of the generic drugs in the market easier by imposition of Abbreviated New Drug Applications (ANDA), which demands only the requirement of bioequivalence of the generic version with the patented drug. In addition, an increasing prevalence of chronic diseases such as cancer and tuberculosis is also a major catalyst which is amplifying the market growth. The National Institute of Cancer Prevention and Research has estimated that there are around 2.5 million people in India, who are living with cancer. However, it has been witnessed that there is still an existence of skeptical thinking among some doctors and patients regarding the usage of clinically equivalent generic drugs over the branded drugs. This makes the physicians provide “dispense as written” prescriptions to the patients, where pharmacists can only dispense the written branded drug and no other alternative drug, which eventually acts as a hindrance for the market growth. In the very market, the key players compete on the basis of the premium launch of their generic version of original drug, as the launch time of generic drugs has a high influence on the adoption of that particular drug. Teva Pharmaceutical Industries, Ltd has recently announced the launch of generic Uceris®, extended-release tablets, 9 mg, in the U.S. which will gradually witness an increased adoption in the near future. The report provides detailed qualitative and quantitative analysis of the Generic Drugs market. Market size and forecast in terms of value and volume has been provided for the period - (2017 - 2025), for the segments namely brand and therapeutic Application in each of the major regions.

Generic Drugs Market Segmentation

By Brand  • Pure generic drugs • Branded generic drugs By Therapeutic Application  • Central nervous system (CNS) • Cardiovascular • Dermatology • Oncology • Respiratory • Others By geography • North America o U.S. o Canada o Mexico • Europe o U.K. o France o Germany o Italy o Spain o Rest of Europe • Asia-Pacific o China o Japan o India o Korea o Rest of APAC • South America o Brazil o Rest of South America • Rest of the World o Middle East o Africa

CHAPTER 1. INTRODUCTION
1.1. RESEARCH METHODOLOGY
1.1.1. ERC DESK RESEARCH
1.1.2. ERC DATA SYNTHESIS
1.1.3. DATA VALIDATION AND MARKET FEEDBACK
1.1.4. ERC DATA SOURCES

CHAPTER 2. GENERIC DRUGS MARKET OVERVIEW
2.1. GENERIC DRUGS MARKET INTRODUCTION
2.2. GLOBAL GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
2.2.1. GLOBAL GENERIC DRUGS PRODUCTION (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.3. GLOBAL GENERIC DRUGS MARKET CAPACITY AND GROWTH RATE, 2017-2025
2.3.1. GLOBAL GENERIC DRUGS CAPACITY (VOLUME) AND GROWTH RATE (%), (2017-2025)
2.4. GLOBAL GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
2.4.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND GROWTH RATE (%), (2017-2025)
2.5. GLOBAL GENERIC DRUGS MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
2.5.1. GLOBAL GENERIC DRUGS CONSUMPTION (VOLUME) AND GROWTH RATE (%), (2017-2025)

CHAPTER 3. GLOBAL GENERIC DRUGS MARKET BY BRAND, 2017-2025
3.1. PURE GENERIC DRUGS
3.2. BRANDED GENERIC DRUGS
3.3. GLOBAL GENERIC DRUGS MARKET REVENUE BY BRAND, 2017-2025
3.3.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY BRAND, 2017-2025
3.3.2. PURE GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
3.3.3. BRANDED GENERIC DRUGS MARKET REVENUE AND GROWTH RATE, 2017-2025
3.4. GLOBAL GENERIC DRUGS MARKET PRODUCTION BY BRAND, 2017-2025
3.4.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY BRAND, 2017-2025
3.4.2. PURE GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025
3.4.3. BRANDED GENERIC DRUGS MARKET PRODUCTION AND GROWTH RATE, 2017-2025

CHAPTER 4. GLOBAL GENERIC DRUGS MARKET BY THERAPEUTIC APPLICATION, 2017-2025
4.1. CENTRAL NERVOUS SYSTEM (CNS)
4.2. CARDIOVASCULAR
4.3. DERMATOLOGY
4.4. ONCOLOGY
4.5. RESPIRATORY
4.6. OTHERS
4.7. GLOBAL GENERIC DRUGS MARKET REVENUE BY THERAPEUTIC APPLICATION, 2017-2025
4.7.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY THERAPEUTIC APPLICATION, 2017-2025
4.7.2. CENTRAL NERVOUS SYSTEM (CNS) MARKET REVENUE AND GROWTH RATE, 2017-2025
4.7.3. CARDIOVASCULAR MARKET REVENUE AND GROWTH RATE, 2017-2025
4.7.4. DERMATOLOGY MARKET REVENUE AND GROWTH RATE, 2017-2025
4.8. GLOBAL GENERIC DRUGS MARKET CONSUMPTION BY THERAPEUTIC APPLICATION, 2017-2025
4.8.1. GLOBAL GENERIC DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY THERAPEUTIC APPLICATION, 2017-2025
4.8.2. CENTRAL NERVOUS SYSTEM (CNS) MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.8.3. CARDIOVASCULAR MARKET CONSUMPTION AND GROWTH RATE, 2017-2025
4.8.4. DERMATOLOGY MARKET CONSUMPTION AND GROWTH RATE, 2017-2025

CHAPTER 5. GLOBAL GENERIC DRUGS MARKET BY REGION, 2017-2025
5.1. NORTH AMERICA
5.1.1. U.S.
5.1.2. CANADA
5.1.3. MEXICO
5.2. EUROPE
5.2.1. U.K.
5.2.2. FRANCE
5.2.3. GERMANY
5.2.4. ITALY
5.2.5. SPAIN
5.2.6. REST OF EUROPE
5.3. ASIA PACIFIC
5.3.1. CHINA
5.3.2. JAPAN
5.3.3. INDIA
5.3.4. KOREA
5.3.5. REST OF APAC
5.4. SOUTH AMERICA
5.4.1. BRAZIL
5.4.2. REST OF SOUTH AMERICA
5.5. REST OF THE WORLD
5.5.1. MIDDLE EAST
5.5.2. AFRICA
5.6. GLOBAL GENERIC DRUGS MARKET REVENUE BY REGION, 2017-2025
5.6.1. GLOBAL GENERIC DRUGS MARKET REVENUE (MILLION USD) AND SHARE (%) BY REGION, 2017-2025
5.6.2. NORTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.3. EUROPE MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.4. ASIA PACIFIC MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.5. SOUTH AMERICA MARKET REVENUE AND GROWTH RATE, 2017-2025
5.6.6. REST OF THE WORLD MARKET REVENUE AND GROWTH RATE, 2017-2025

CHAPTER 6. GLOBAL GENERIC DRUGS MARKET PRODUCTION AND CONSUMPTION ANALYSIS BY REGION, 2017-2025
6.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION ANALYSIS BY REGION, 2017-2025
6.1.1. GLOBAL GENERIC DRUGS MARKET PRODUCTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
6.1.2. GLOBAL GENERIC DRUGS MARKET CONSUMPTION (VOLUME) AND SHARE (%) BY REGION, 2017-2025
6.1.3. NORTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.4. EUROPE MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.5. ASIA PACIFIC MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.6. SOUTH AMERICA MARKET PRODUCTION AND CONSUMPTION, 2017-2025
6.1.7. REST OF THE WORLD MARKET PRODUCTION AND CONSUMPTION, 2017-2025

CHAPTER 7. MARKET DETERMINANTS
7.1. MARKET DRIVERS
7.2. MARKET RESTRAINTS
7.3. MARKET OPPORTUNITIES
7.4. MARKET DETERMINANTS RADAR CHART

CHAPTER 8. GLOBAL GENERIC DRUGS MARKET COMPETITION BY MANUFACTURERS
8.1. GLOBAL GENERIC DRUGS PRODUCTION AND SHARE BY MANUFACTURERS (2017-2025)
8.1.1. GLOBAL GENERIC DRUGS PRODUCTION (VOLUME) AND SHARE (%) BY MANUFACTURERS (2017-2025)
8.2. GLOBAL GENERIC DRUGS REVENUE AND SHARE BY MANUFACTURERS (2017-2025)
8.2.1. GLOBAL GENERIC DRUGS REVENUE (MILLION USD) AND SHARE (%) BY MANUFACTURERS (2017-2025)
8.3. GENERIC DRUGS MARKET COMPETITIVE SITUATION AND TRENDS
8.3.1. GENERIC DRUGS MARKET SHARE (%) OF TOP 3 MANUFACTURERS
8.3.2. GENERIC DRUGS MARKET SHARE (%) OF TOP 5 MANUFACTURERS

CHAPTER 9. GLOBAL GENERIC DRUGS MANUFACTURERS ANALYSIS
9.1. RANBAXY LABORATORIES, LTD
9.1.1. BUSINESS OVERVIEW
9.1.2. COMPANY BASIC INFORMATION
9.1.3. GENERIC DRUGS PRODUCT DETAILS
9.1.4. RANBAXY LABORATORIES, LTD GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.2. ACTAVIS
9.2.1. BUSINESS OVERVIEW
9.2.2. COMPANY BASIC INFORMATION
9.2.3. GENERIC DRUGS PRODUCT DETAILS
9.2.4. ACTAVIS GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.3. MYLAN, INC.
9.3.1. BUSINESS OVERVIEW
9.3.2. COMPANY BASIC INFORMATION
9.3.3. GENERIC DRUGS PRODUCT DETAILS
9.3.4. MYLAN, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.4. TEVA PHARMACEUTICAL INDUSTRIES, LTD.
9.4.1. BUSINESS OVERVIEW
9.4.2. COMPANY BASIC INFORMATION
9.4.3. GENERIC DRUGS PRODUCT DETAILS
9.4.4. TEVA PHARMACEUTICAL INDUSTRIES, LTD. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.5. SANDOZ INTERNATIONAL GMBH
9.5.1. BUSINESS OVERVIEW
9.5.2. COMPANY BASIC INFORMATION
9.5.3. GENERIC DRUGS PRODUCT DETAILS
9.5.4. SANDOZ INTERNATIONAL GMBH GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.6. DR. REDDY’S LABORATORIES
9.6.1. BUSINESS OVERVIEW
9.6.2. COMPANY BASIC INFORMATION
9.6.3. GENERIC DRUGS PRODUCT DETAILS
9.6.4. DR. REDDY’S LABORATORIES GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.7. PAR PHARMACEUTICAL, INC.
9.7.1. BUSINESS OVERVIEW
9.7.2. COMPANY BASIC INFORMATION
9.7.3. GENERIC DRUGS PRODUCT DETAILS
9.7.4. PAR PHARMACEUTICAL, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.8. APOTEX, INC.
9.8.1. BUSINESS OVERVIEW
9.8.2. COMPANY BASIC INFORMATION
9.8.3. GENERIC DRUGS PRODUCT DETAILS
9.8.4. APOTEX, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.9. HOSPIRA, INC.
9.9.1. BUSINESS OVERVIEW
9.9.2. COMPANY BASIC INFORMATION
9.9.3. GENERIC DRUGS PRODUCT DETAILS
9.9.4. HOSPIRA, INC. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN
9.10. WATSON PHARMACEUTICALS, LTD.
9.10.1. BUSINESS OVERVIEW
9.10.2. COMPANY BASIC INFORMATION
9.10.3. GENERIC DRUGS PRODUCT DETAILS
9.10.4. WATSON PHARMACEUTICALS, LTD. GENERIC DRUGS PRODUCTION, REVENUE AND GROSS MARGIN

CHAPTER 10. GENERIC DRUGS MARKET VALUE CHAIN ANALYSIS
10.1. GENERIC DRUGS INDUSTRIAL CHAIN ANALYSIS
10.2. GENERIC DRUGS KEY RAW MATERIALS ANALYSIS
10.2.1. KEY RAW MATERIALS
10.2.2. PRICE TREND OF KEY RAW MATERIALS
10.2.3. KEY SUPPLIERS OF RAW MATERIALS
10.3. CONSUMER ANALYSIS
10.3.1. CONSUMER 1
10.3.2. CONSUMER 2
10.3.3. CONSUMER 3
10.3.4. CONSUMER 4

• Ranbaxy Laboratories, Ltd
• Actavis
• Mylan, Inc.
• Teva Pharmaceutical Industries, Ltd.
• Sandoz International GmbH
• Dr. Reddy’s Laboratories
• Apotex, Inc.
• Par Pharmaceutical, Inc.
• Hospira, Inc.
• Watson Pharmaceuticals, Ltd.
• Others

Select License Type

  • $4700
  • $5600
  • $2000
  • Buy Now

Report Highlights:

Complete overview of market
Major drivers, restrain, opportunities, and challenges of the market
Market Trends and how they are boosting the market growth
Changing dynamics in the Market
Complete overview of the market
Historical, Base year, projected, and current market size in terms of value and volume
COVID-19 Impact analysis of the market
Current industry trends and developments

CLIENTS

Esticast Logo

CORPORATE OFFICE

location  (US)

1055 West 7th Street, Los Angeles, CA 90017 (P) US

phone  +1-213-262-0704
location  (APAC Address)

Office No. 407, Navale Icon IT Park, Near Navale Bridge, Narhe, Pune, Maharashtra 411041

phone  +91-959-503-5024

COMPANY

SECURE ONLINE PAYMENTS

  • visa
  • mastercard
  • amex
  • discover

FOLLOW US

  • facebook
  • linkedin
  • phone
  • youtube
© 2022 | All Rights Reserved by Esticast Research & Consulting